

**Raffles Medical Group Ltd
and its Subsidiaries**
Registration Number : 198901967K

Condensed Financial Statements
For the six months and full year ended
31 December 2022

Table of contents

A.	Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	1
B.	Condensed Statements of Financial Position	3
C.	Condensed Consolidated Statement of Cash Flows	4
D.	Condensed Statements of Changes in Equity	5
E.	Notes to the Condensed Consolidated Financial Statements	8
F.	Other Information Required by Listing Rule Appendix 7.2	23

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

Condensed Consolidated Statement of Profit or Loss	Note	6 months	6 months	Change	12 months	12 months	Change
		ended 31 December 2022 S\$'000	ended 31 December 2021 S\$'000	%	ended 31 December 2022 S\$'000	ended 31 December 2021 S\$'000	%
Revenue		384,233	379,976	1.1	766,537	723,791	5.9
Other operating income		1,082	6,448	(83.2)	7,957	13,849	(42.5)
Inventories and consumables used		(29,735)	(41,247)	(27.9)	(61,112)	(82,013)	(25.5)
Purchased and contracted services		(35,732)	(30,882)	15.7	(65,444)	(61,257)	6.8
Staff costs		(145,627)	(204,075)	(28.6)	(341,746)	(386,973)	(11.7)
Depreciation of property, plant and equipment		(18,248)	(19,380)	(5.8)	(37,513)	(36,725)	2.1
Amortisation of intangible assets		(1,342)	(1,466)	(8.5)	(2,703)	(2,601)	3.9
Operating lease expenses		(966)	(861)	12.2	(1,791)	(1,744)	2.7
Impairment loss on trade receivables		(257)	(261)	(1.5)	(1,023)	(1,495)	(31.6)
Impairment loss on property, plant and equipment		(9,958)	-	nm	(9,958)	-	nm
Impairment loss on intangible assets and goodwill		(7,338)	(3,780)	94.1	(7,338)	(3,780)	94.1
Other operating expenses		(26,643)	(19,229)	38.6	(50,020)	(39,746)	25.8
Profit from operating activities		109,469	65,243	67.8	195,846	121,306	61.4
Finance income		2,161	299	nm	2,740	634	nm
Finance costs		(3,409)	(3,549)	(3.9)	(6,882)	(6,356)	8.3
Profit before tax	6	108,221	61,993	74.6	191,704	115,584	65.9
Tax expense	7	(24,481)	(17,117)	43.0	(48,002)	(31,868)	50.6
Profit for the period/year		83,740	44,876	86.6	143,702	83,716	71.7
Profit attributable to:							
Owners of the Company		83,845	44,726	87.5	143,516	84,171	70.5
Non-controlling interests		(105)	150	nm	186	(455)	nm
Profit for the period/year		83,740	44,876	86.6	143,702	83,716	71.7

Note: nm denotes not meaningful.

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (cont'd)

Condensed Consolidated Statement of Other Comprehensive Income	6 months ended 31 December 2022	6 months ended 31 December 2021	Change	12 months ended 31 December 2022	12 months ended 31 December 2021	Change
	S\$'000	S\$'000	%	S\$'000	S\$'000	%
Profit for the period/year	83,740	44,876	86.6	143,702	83,716	71.7
Other comprehensive income						
Item that is or may be reclassified subsequently to profit or loss:						
Foreign currency translation differences - foreign operations	(17,738)	4,346	nm	(22,769)	11,078	nm
Total comprehensive income for the period/year	66,002	49,222	34.1	120,933	94,794	27.6
Total comprehensive income attributable to:						
Owners of the Company	66,745	48,754	36.9	121,409	94,369	28.7
Non-controlling interests	(743)	468	nm	(476)	425	nm
Total comprehensive income for the period/year	66,002	49,222	34.1	120,933	94,794	27.6
Earnings per share						
Basic earnings per share (cents) [A]	4.52	2.39	89.1	7.73	4.51	71.4
Diluted earnings per share (cents) [B]	4.50	2.38	89.1	7.69	4.49	71.3

[A] The calculation of earnings per share for the second half and full year ended 31 December 2022 were based on the weighted average number of ordinary shares 1,853,293,901 (2H 2021: 1,868,994,182) and 1,857,198,582 (FY 2021: 1,867,546,983) in issue during the period.

[B] The calculation of earnings per share (on a fully diluted basis) for the second half and full year ended 31 December 2022 were based on the weighted average number of ordinary shares 1,864,522,856 (2H 2021: 1,882,484,573) and 1,866,347,071 (FY 2021: 1,876,459,936) in issue during the period.

Explanatory Notes to the Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

- Lower government grants received in 2H 2022 and, accordingly FY 2022 in totality, resulted in other operating income decreasing by 83.2% and 42.5% respectively when compared to the previous corresponding periods.
- Fewer COVID-19 PCR tests conducted in 2H 2022 and FY 2022 contributed to lower inventories and consumables cost.
- Higher insurance claims due to increase in insurance business resulted in higher purchased and contracted services expense for 2H 2022 and FY 2022.
- The phasing out of Covid-19 projects in 2H 2022, resulted in a reduction in manning requirements. As a result, staff costs decreased by 28.6% and 11.7% in 2H 2022 and FY 2022 respectively.
- The increase in other operating expenses in 2H 2022 and FY 2022 was mainly due to higher utilities charges, professional fees and foreign exchange losses.

Condensed Statements of Financial Position As at 31 December 2022

	Note	Group		Company	
		31 December 2022 S\$'000	31 December 2021 S\$'000	31 December 2022 S\$'000	31 December 2021 S\$'000
Non-current assets					
Property, plant and equipment	11	739,072	797,362	7,406	3,788
Intangible assets and goodwill	10	20,274	31,830	556	875
Investment properties	12	273,400	274,000	–	–
Subsidiaries		–	–	857,298	724,603
Deferred tax assets		2,425	1,138	392	322
Trade and other receivables		2,274	1,857	4,657	5,024
		<u>1,037,445</u>	<u>1,106,187</u>	<u>870,309</u>	<u>734,612</u>
Current assets					
Inventories		13,098	13,374	2,163	3,024
Trade and other receivables		194,032	160,737	151,355	175,985
Cash and cash equivalents		253,127	264,988	121,084	137,708
		<u>460,257</u>	<u>439,099</u>	<u>274,602</u>	<u>316,717</u>
Total assets		<u>1,497,702</u>	<u>1,545,286</u>	<u>1,144,911</u>	<u>1,051,329</u>
Equity attributable to owners of the Company					
Share capital	14	432,379	426,346	432,379	426,346
Reserves		582,675	534,448	562,132	428,470
		<u>1,015,054</u>	<u>960,794</u>	<u>994,511</u>	<u>854,816</u>
Non-controlling interests		15,350	15,826	–	–
Total equity		<u>1,030,404</u>	<u>976,620</u>	<u>994,511</u>	<u>854,816</u>
Non-current liabilities					
Loans and borrowings	13	63,376	77,914	10,000	37,914
Trade and other payables		56,478	50,316	21,842	8,582
Lease liabilities		13,441	13,678	1,822	117
Deferred tax liabilities		8,303	10,147	–	–
		<u>141,598</u>	<u>152,055</u>	<u>33,664</u>	<u>46,613</u>
Current liabilities					
Loans and borrowings	13	9,667	96,297	9,667	18,546
Current tax liabilities		49,631	29,095	30,056	14,669
Trade and other payables		223,771	253,568	76,534	116,378
Lease liabilities		9,659	10,243	479	307
Other financial liabilities		2,744	2,761	–	–
Insurance contract provisions		30,228	24,647	–	–
		<u>325,700</u>	<u>416,611</u>	<u>116,736</u>	<u>149,900</u>
Total liabilities		<u>467,298</u>	<u>568,666</u>	<u>150,400</u>	<u>196,513</u>
Total equity and liabilities		<u>1,497,702</u>	<u>1,545,286</u>	<u>1,144,911</u>	<u>1,051,329</u>

Explanatory Notes to the Condensed Statements of Financial Position

- Property, plant and equipment decrease mainly due to effect of movements in exchange rate, increase in depreciation expense on account of Raffles Hospital Shanghai being operational for a full year in FY 2022 and impairment loss on property, plant and equipment.
- Intangible assets and goodwill decreased mainly due to impairment loss on goodwill.
- Increase in Trade and other receivables was due to higher volume of business generated by the Group in FY 2022.
- Current tax liabilities increased in tandem with better financial performance in FY 2022.
- Loans and borrowings decreased mainly due to repayment of bank loan.
- Insurance contract provisions increased by S\$5.6 million, mainly due to higher provision for unearned premiums resulting from billings for premium from the Group's insurance business.

Condensed Consolidated Statement of Cash Flows

	Group			
	6 months ended 31 December 2022	6 months ended 31 December 2021	12 months ended 31 December 2022	12 months ended 31 December 2021
	S\$'000	S\$'000	S\$'000	S\$'000
Cash flows from operating activities				
Profit for the period/year	83,740	44,876	143,702	83,716
<i>Adjustments for :</i>				
Amortisation of intangible assets	1,342	1,466	2,703	2,601
Changes in fair value of investment properties	600	(414)	600	(414)
Depreciation of property, plant and equipment	18,248	19,380	37,513	36,725
Equity-settled share-based payment transactions	1,647	1,357	3,160	2,469
Finance costs	3,409	3,549	6,882	6,356
Finance income	(2,161)	(299)	(2,740)	(634)
Gain on lease modification and derecognition	(100)	(91)	(120)	(120)
(Gain)/Loss on disposal of property, plant and equipment, net	(33)	68	(18)	59
Impairment loss on intangible assets and goodwill	7,338	3,780	7,338	3,780
Impairment loss on property, plant and equipment	9,958	–	9,958	–
Intangible asset written off	9	–	9	–
Property, plant and equipment written off	1,201	1,220	1,244	1,278
Tax expense	24,481	17,117	48,002	31,868
	149,679	92,009	258,233	167,684
<i>Changes in working capital:</i>				
Insurance contract provisions	(4,446)	(8,737)	5,581	169
Inventories	(538)	1,123	276	1,213
Trade and other payables	(7,702)	36,740	(7,010)	61,113
Trade and other receivables	(61,110)	(33,969)	(31,709)	(48,325)
Cash generated from operations	75,883	87,166	225,371	181,854
Tax paid	(14,558)	(10,237)	(29,146)	(21,742)
Net cash from operating activities	61,325	76,929	196,225	160,112
Cash flows from investing activities				
Acquisition of intangible assets	(142)	(2,173)	(286)	(2,864)
Capitalised expenditure on investment properties	–	–	–	(65)
Interest received	1,875	303	2,306	625
Proceeds from disposal of property, plant and equipment	144	32	161	45
Purchase of property, plant and equipment	(13,346)	(9,920)	(25,013)	(49,940)
Net cash used in investing activities	(11,469)	(11,758)	(22,832)	(52,199)
Cash flows from financing activities				
Acquisition of own shares	(787)	(3,230)	(24,344)	(3,230)
Dividends paid to owners of the Company	–	–	(52,015)	(37,349)
Interest paid	(2,953)	(3,591)	(6,256)	(6,729)
Lease interest paid	(319)	(259)	(540)	(576)
Loan from subsidiary's non-controlling interest	–	3,302	–	7,467
Payment of lease liabilities	(5,962)	(5,950)	(12,165)	(11,542)
Proceeds from bank loans	77,690	7,194	85,609	39,547
Proceeds from issue of shares under share option scheme	1,602	3,091	6,033	5,595
Repayment of bank loans	(153,895)	(16,782)	(180,024)	(40,056)
Net cash used in financing activities	(84,624)	(16,225)	(183,702)	(46,873)
Net (decrease)/increase in cash and cash equivalents	(34,768)	48,946	(10,309)	61,040
Cash and cash equivalents at 1 July / 1 January	287,954	214,665	263,908	202,057
Effect of exchange rate fluctuations on cash held	(1,132)	297	(1,545)	811
Cash and cash equivalents at 31 December	252,054	263,908	252,054	263,908

Explanatory Notes to the Condensed Consolidated Statement of Cash Flows

The cash and cash equivalents for the statement of cash flows presentation excluded an amount of S\$1.1 million (US\$0.8 million) deposited in an escrow account of a subsidiary. The Group's cash and cash equivalents reduced from S\$263.9 million as at 31 December 2021 to S\$252.1 million as at 31 December 2022. This was mainly due to net repayment of bank loans of S\$94.4 million, purchase of property, plant and equipment of S\$25.0 million, acquisition of own shares of S\$24.3 million as well as dividend payment of S\$52.0 million, despite strong operating cashflows generated by the Group.

Condensed Statements of Changes in Equity

Group	Share capital S\$'000	Translation reserve S\$'000	Equity compensation reserve S\$'000	Revaluation reserve S\$'000	Other reserve S\$'000	Reserve for own shares S\$'000	Accumulated profits S\$'000	Total attributable to owners of the Company S\$'000	Non-controlling interests S\$'000	Total equity S\$'000
At 1 January 2022	426,346	9,089	33,061	16,367	(4,818)	(3,230)	483,979	960,794	15,826	976,620
Total comprehensive income for the year										
Profit for the year	-	-	-	-	-	-	143,516	143,516	186	143,702
Other comprehensive income										
Foreign currency translation differences - foreign operations	-	(22,107)	-	-	-	-	-	(22,107)	(662)	(22,769)
Total other comprehensive income for the year	-	(22,107)	-	-	-	-	-	(22,107)	(662)	(22,769)
Total comprehensive income for the year	-	(22,107)	-	-	-	-	143,516	121,409	(476)	120,933
Transactions with owners, recognised directly in equity										
Contributions by and distributions to owners										
Issue of shares upon the exercise of options under Raffles Medical Group Employees' Share Option Schemes	6,033	-	-	-	-	-	-	6,033	-	6,033
Own shares acquired	-	-	-	-	-	(24,344)	-	(24,344)	-	(24,344)
Own shares reissued pursuant to Raffles Medical Group Performance Share Plan	-	-	(463)	-	(217)	680	-	-	-	-
Value of employee services received for issue of share options and share awards	-	-	3,160	-	-	-	-	3,160	-	3,160
Final dividend paid of 2.80 cents per ordinary share – Cash	-	-	-	-	-	-	(52,015)	(52,015)	-	(52,015)
Total contributions by and distributions to owners	6,033	-	2,697	-	(217)	(23,664)	(52,015)	(67,166)	-	(67,166)
Changes in ownership interests in subsidiaries										
Present value of the exercise price of written put options	-	-	-	-	17	-	-	17	-	17
Total changes in ownership interests in subsidiaries	-	-	-	-	17	-	-	17	-	17
Total transactions with owners	6,033	-	2,697	-	(200)	(23,664)	(52,015)	(67,149)	-	(67,149)
At 31 December 2022	432,379	(13,018)	35,758	16,367	(5,018)	(26,894)	575,480	1,015,054	15,350	1,030,404

Condensed Statements of Changes in Equity (cont'd)

Group	Share capital S\$'000	Translation reserve S\$'000	Equity compensation reserve S\$'000	Revaluation reserve S\$'000	Other reserve S\$'000	Reserve for own shares S\$'000	Accumulated profits S\$'000	Total attributable to owners of the Company S\$'000	Non-controlling interests S\$'000	Total equity S\$'000
At 1 January 2021	420,966	(1,109)	30,671	16,367	(4,656)	(400)	437,157	898,996	15,401	914,397
Total comprehensive income for the year										
Profit for the year	–	–	–	–	–	–	84,171	84,171	(455)	83,716
Other comprehensive income										
Foreign currency translation differences - foreign operations	–	10,198	–	–	–	–	–	10,198	880	11,078
Total other comprehensive income for the year	–	10,198	–	–	–	–	–	10,198	880	11,078
Total comprehensive income for the year	–	10,198	–	–	–	–	84,171	94,369	425	94,794
Transactions with owners, recognised directly in equity										
Contributions by and distributions to owners										
Issue of shares upon the exercise of options under Raffles Medical Group Employees' Share Option Schemes	5,301	–	–	–	–	–	–	5,301	–	5,301
Issue of shares to employees under Raffles Medical Group Performance Share Plan	79	–	(79)	–	–	–	–	–	–	–
Own shares acquired	–	–	–	–	–	(3,230)	–	(3,230)	–	(3,230)
Own shares reissued pursuant to Raffles Medical Group Employees' Share Option Schemes	–	–	–	–	(106)	400	–	294	–	294
Value of employee services received for issue of share options and share awards	–	–	2,469	–	–	–	–	2,469	–	2,469
Final dividend paid of 2.00 cents per ordinary share – Cash	–	–	–	–	–	–	(37,349)	(37,349)	–	(37,349)
Total contributions by and distributions to owners	5,380	–	2,390	–	(106)	(2,830)	(37,349)	(32,515)	–	(32,515)
Changes in ownership interests in subsidiaries										
Present value of the exercise price of written put options	–	–	–	–	(56)	–	–	(56)	–	(56)
Total changes in ownership interests in subsidiaries	–	–	–	–	(56)	–	–	(56)	–	(56)
Total transactions with owners	5,380	–	2,390	–	(162)	(2,830)	(37,349)	(32,571)	–	(32,571)
At 31 December 2021	426,346	9,089	33,061	16,367	(4,818)	(3,230)	483,979	960,794	15,826	976,620

Condensed Statements of Changes in Equity (cont'd)

Company	Share	Equity	Other	Reserve	Accumulated	Total
	capital	compensation	reserve	for own	profits	
	S\$'000	S\$'000	S\$'000	shares	S\$'000	S\$'000
At 1 January 2022	426,346	33,061	(106)	(3,230)	398,745	854,816
Total comprehensive income for the year						
Profit for the year	–	–	–	–	206,861	206,861
Total comprehensive income for the year	–	–	–	–	206,861	206,861
Transactions with owners, recognised directly in equity						
Contributions by and distributions to owners						
Issue of shares upon the exercise of options under Raffles Medical Group Employees' Share Option Schemes	6,033	–	–	–	–	6,033
Own shares acquired	–	–	–	(24,344)	–	(24,344)
Own shares reissued pursuant to Raffles Medical Group Performance Share Plan	–	(463)	(217)	680	–	–
Value of employee services received for issue of share options and share awards	–	3,160	–	–	–	3,160
Final dividend paid of 2.80 cents per ordinary share - Cash	–	–	–	–	(52,015)	(52,015)
Total contributions by and distributions to owners	6,033	2,697	(217)	(23,664)	(52,015)	(67,166)
At 31 December 2022	432,379	35,758	(323)	(26,894)	553,591	994,511
At 1 January 2021	420,966	30,671	–	(400)	296,874	748,111
Total comprehensive income for the year						
Profit for the year	–	–	–	–	139,220	139,220
Total comprehensive income for the year	–	–	–	–	139,220	139,220
Transactions with owners, recognised directly in equity						
Contributions by and distributions to owners						
Issue of shares upon the exercise of options under Raffles Medical Group Employees' Share Option Schemes	5,301	–	–	–	–	5,301
Issue of shares to employees under Raffles Medical Group Performance Share Plan	79	(79)	–	–	–	–
Own shares acquired	–	–	–	(3,230)	–	(3,230)
Own shares reissued pursuant to Raffles Medical Group Employees' Share Option Scheme	–	–	(106)	400	–	294
Value of employee services received for issue of share options and share awards	–	2,469	–	–	–	2,469
Final dividend paid of 2.00 cents per ordinary share - Cash	–	–	–	–	(37,349)	(37,349)
Total contributions by and distributions to owners	5,380	2,390	(106)	(2,830)	(37,349)	(32,515)
At 31 December 2021	426,346	33,061	(106)	(3,230)	398,745	854,816

Notes to the Condensed Financial Statements

1 Corporate information

Raffles Medical Group Ltd (the Company) is a company incorporated in Singapore. The address of the Company's registered office is 585 North Bridge Road, Raffles Hospital #11-00, Singapore 188770.

These condensed financial statements as at and for the six months and full year ended 31 December 2022 comprise the Company and its subsidiaries (together referred to as the Group).

The principal activities of the Company are those relating to the operation of medical clinics, other general medical services and investment holdings.

The Group and the Company are the sole proprietor of the following:

- Family Doctors
- RafflesCare
- Raffles Airport Medical Centre
- Raffles Corporate Wellness
- Raffles Dental Surgery
- Raffles Healthcare Consultancy
- Raffles Healthcare Institute
- Raffles Health Screeners
- Raffles Medical Management
- Raffles Medihelp
- Raffles Optica
- Raffles Pharmacare
- Raffles Pharmacy
- Raffles Solitaire
- Raffles Solitaire International
- Raffles Specialist Centre

The Group and the Company are partners of the following:

- Changi Medical Services LLP
- Raffles International Medical Assistance LLP

All transactions of these sole proprietorships and partnerships are reflected in the condensed financial statements of the Company.

The immediate and ultimate holding company during the financial year is Raffles Medical Holdings Pte Ltd, which is incorporated in Singapore.

2 Basis of preparation

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance of the Group since the last interim financial statements for the period ended 30 June 2022.

The condensed financial statements are presented in Singapore dollar which is the Company's functional currency.

2.1 New standards and amendments

The Group has applied the following amendments to SFRS(I) for the first time for the annual period beginning on 1 January 2022:

- Amendment to SFRS(I) 16: *COVID-19-Related Rent Concessions beyond 30 June 2021*
- Amendments to SFRS(I) 3: *Reference to the Conceptual Framework*
- Amendments to SFRS(I) 1-16: *Property, Plant and Equipment – Proceeds before Intended Use*
- Amendments to SFRS(I) 1-37: *Onerous Contracts – Cost of Fulfilling a Contract*
- Annual Improvements to SFRS(I)s 2018-2020

The application of these amendments to standards does not have a material effect on the financial statements.

2.2 Use of estimates and judgements

In preparing the condensed financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 December 2021.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised prospectively.

Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the condensed financial statements is on lease term and whether the Group is reasonably certain to exercise extension options. Some property leases contain extension options exercisable by the Group up to one year before the end of the non-cancellable contract period. Where practicable, the Group seeks to include extension options in new leases to provide operational flexibility. The extension options held are exercisable only by the Group and not by the lessors. The Group assesses at lease commencement date whether it is reasonably certain to exercise the extension options. The Group reassesses whether it is reasonably certain to exercise the options if there is a significant event or significant changes in circumstances within its control. The Group expects to make use of all extension options in the lease contracts, which typically vary between 1 and 3 years.

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next financial year are included in the following notes:

Note 10 - impairment test of intangible assets and goodwill: key assumptions underlying recoverable amounts
Note 12 - determination of fair value of investment properties on the basis of significant unobservable inputs

2.2 Use of estimates and judgements (cont'd)

Measurement of fair values

A number of the Group's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities.

If third party information, such as property valuation report, is used to measure fair values, the Group assesses the evidence obtained from the third parties to support the conclusion that these valuations meet the requirements of SFRS(I), including the level in the fair value hierarchy in which the valuations should be classified. Significant valuation issues are reported to the Audit & Risk Committee.

3 Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial periods.

4 Segment and revenue information

The Group has 3 reportable segments, as described below, which are the Group's strategic business units. The strategic business units offer different products and services, and are managed separately because they require different technology and marketing strategies. For each of the strategic business units, the Group's Executive Chairman reviews internal management reports regularly. The following summary describes the operations in each of the Group's reportable segments:

Healthcare services : The operations of medical clinics and other general medical services; provision of health insurance, trading in pharmaceutical and nutraceutical products and diagnostic equipment, and provision of management and consultancy services.

Hospital services : The provision of specialised medical services and operation of hospitals and business of medical laboratory and imaging centre.

Investment holdings : Investment holdings and those relating to investment properties.

Performance is measured based on segment profit before tax, as included in the internal management reports that are reviewed by the Group's Executive Chairman. Segment profit is used to measure performance as management believes that such information is most relevant in evaluating the results of certain segments relative to other entities operating within these businesses.

Inter-segment pricing is determined on mutually agreed terms.

Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Unallocated items mainly comprise current tax and deferred tax liabilities and assets.

Segment capital expenditure is the total cost incurred during the period to acquire segment assets that are expected to be used for more than one period.

4.1 Reportable segments

	Healthcare services		Hospital services		Investment holdings		Total	
	31 December 2022	31 December 2021	31 December 2022	31 December 2021	31 December 2022	31 December 2021	31 December 2022	31 December 2021
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Revenue and expenses								
Revenue	498,343	458,749	316,277	346,101	45,886	39,691	860,506	844,541
Inter-segment revenue	7,613	15,196	47,628	72,608	38,728	32,946	93,969	120,750
Finance costs	(934)	(797)	(39)	(11)	(5,909)	(5,548)	(6,882)	(6,356)
Depreciation and amortisation	(16,631)	(16,889)	(11,160)	(11,367)	(188)	(162)	(27,979)	(28,418)
Reportable segment profit before tax	166,664	78,478	21,413	23,955	10,479	23,534	198,556	125,967
Other material non-cash items:								
- Impairment loss on intangible assets and goodwill	(7,327)	(3,780)	(11)	-	-	-	(7,338)	(3,780)
- Impairment loss on property, plant and equipment	-	-	-	-	(9,958)	-	(9,958)	-
- Impairment loss on trade receivable	(413)	(917)	(610)	(741)	-	163	(1,023)	(1,495)
Reportable segment assets	1,242,554	1,175,191	232,149	287,000	962,977	1,022,846	2,437,680	2,485,037
Capital expenditure	17,453	7,445	5,087	25,048	386	31,207	22,926	63,700
Reportable segment liabilities	255,630	318,406	184,313	222,183	757,132	797,131	1,197,075	1,337,720

4.1 Reportable segments (cont'd)

Reconciliations of reportable segment revenues, profit or loss, assets and liabilities and other material items

	31 December 2022 S\$'000	31 December 2021 S\$'000
Revenues		
Total revenue for reportable segments	860,506	844,541
Elimination of inter-segment revenue	(93,969)	(120,750)
Consolidated revenue	<u>766,537</u>	<u>723,791</u>
Profit or loss before tax		
Total profit before tax for reportable segments	198,556	125,967
Elimination of inter-segment profits / Consolidation adjustment	5,385	525
Adjustment for depreciation of property, plant and equipment	(12,237)	(10,908)
Consolidated profit before tax	<u>191,704</u>	<u>115,584</u>
Assets		
Total assets for reportable segments	2,437,680	2,485,037
Elimination of inter-segment assets	(942,403)	(940,889)
Unallocated amounts-current tax and deferred tax assets	2,425	1,138
Consolidated total assets	<u>1,497,702</u>	<u>1,545,286</u>
Liabilities		
Total liabilities for reportable segments	1,197,075	1,337,720
Elimination of inter-segment liabilities	(787,711)	(808,296)
Unallocated amounts-current tax and deferred tax liabilities	57,934	39,242
Consolidated total liabilities	<u>467,298</u>	<u>568,666</u>

Other material items

	Reportable segment totals S\$'000	Adjustments S\$'000	Consolidated totals S\$'000
31 December 2022			
Depreciation and amortisation	<u>27,979</u>	<u>12,237</u>	<u>40,216</u>
31 December 2021			
Depreciation and amortisation	<u>28,418</u>	<u>10,908</u>	<u>39,326</u>

The Group's properties at Raffles Holland V, Raffles Hospital, Raffles Specialist Centre, Raffles Hospital Chongqing and Raffles Hospital Shanghai are owned by its subsidiaries and classified as investment properties in the subsidiaries' standalone financial statements. In accordance with the Group's accounting policies, investment property is measured at fair value and not depreciated.

For the preparation of the consolidated financial statements, a portion of these properties are reclassified from investment properties to property, plant and equipment as these properties are used in the supply of medical services by the Group. Accordingly, the carrying values of these properties are depreciated over their useful lives in the consolidated financial statements of the Group.

4.1 Reportable segments (cont'd)

The amount of S\$12,237,000 (2021: S\$10,908,000) relates to the depreciation of these properties for the year ended 31 December 2022.

Geographical information

The Group operations are primarily in Singapore, Greater China, Vietnam, Cambodia and Japan.

In presenting information on the basis of geographical segments, segment revenue is based on the geographical location of customers and segment assets are based on the geographical location of the assets.

	Group	
	31 December 2022 S\$'000	31 December 2021 S\$'000
Revenue		
Singapore	699,752	660,448
Greater China	50,247	49,292
Rest of Asia	16,538	14,051
Consolidated revenue	<u>766,537</u>	<u>723,791</u>
Non-current assets		
Singapore	679,065	686,590
Greater China	347,497	409,338
Rest of Asia	6,184	7,264
Consolidated non-current assets*	<u>1,032,746</u>	<u>1,103,192</u>

* Non-current assets exclude financial instruments and deferred tax assets.

4.2 Disaggregation of Revenue

	Group	
	31 December 2022 S\$'000	31 December 2021 S\$'000
Revenue from contracts with customers	759,429	716,215
Rental income	7,108	7,576
	<u>766,537</u>	<u>723,791</u>

5 Financial assets and financial liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group as at 31 December 2022 and 31 December 2021:

Group	Carrying amount			Fair value			
	At amortised cost S\$'000	Other financial liabilities S\$'000	Total S\$'000	Level 1 S\$'000	Level 2 S\$'000	Level 3 S\$'000	Total S\$'000
31 December 2022							
Financial assets not measured at fair value							
Trade and other receivables #	192,028	–	192,028				
Cash and cash equivalents	253,127	–	253,127				
	<u>445,155</u>	<u>–</u>	<u>445,155</u>				
Financial liabilities not measured at fair value							
Loans and borrowings	–	(73,043)	(73,043)	–	(73,043)	–	(73,043)
Trade and other payables*	–	(271,802)	(271,802)	–	–	–	–
Other financial liabilities	–	(2,744)	(2,744)	–	–	(2,744)	(2,744)
	<u>–</u>	<u>(347,589)</u>	<u>(347,589)</u>				
31 December 2021							
Financial assets not measured at fair value							
Trade and other receivables #	159,287	–	159,287				
Cash and cash equivalents	264,988	–	264,988				
	<u>424,275</u>	<u>–</u>	<u>424,275</u>				
Financial liabilities not measured at fair value							
Loans and borrowings	–	(174,211)	(174,211)	–	(174,211)	–	(174,211)
Trade and other payables*	–	(298,808)	(298,808)	–	–	–	–
Other financial liabilities	–	(2,761)	(2,761)	–	–	(2,761)	(2,761)
	<u>–</u>	<u>(475,780)</u>	<u>(475,780)</u>				

Excludes prepayments

* Excludes deferred income and other long term employee benefits

5 Financial assets and financial liabilities (cont'd)

Company	Carrying amount			Fair value			
	At amortised cost S\$'000	Other financial liabilities S\$'000	Total S\$'000	Level 1 S\$'000	Level 2 S\$'000	Level 3 S\$'000	Total S\$'000
31 December 2022							
Financial assets not measured at fair value							
Trade and other receivables #	154,569	–	154,569				
Cash and cash equivalents	121,084	–	121,084				
Amounts due from subsidiaries	809,836	–	809,836	–	–	809,836	809,836
	<u>1,085,489</u>	<u>–</u>	<u>1,085,489</u>				
Financial liabilities not measured at fair value							
Loans and borrowings	–	(19,667)	(19,667)	–	(19,667)	–	(19,667)
Trade and other payables*	–	(94,513)	(94,513)				
	<u>–</u>	<u>(114,180)</u>	<u>(114,180)</u>				
31 December 2021							
Financial assets not measured at fair value							
Trade and other receivables #	179,548	–	179,548				
Cash and cash equivalents	137,708	–	137,708				
Amounts due from subsidiaries	678,731	–	678,731	–	–	678,731	678,731
	<u>995,987</u>	<u>–</u>	<u>995,987</u>				
Financial liabilities not measured at fair value							
Loans and borrowings	–	(56,460)	(56,460)	–	(56,460)	–	(56,460)
Trade and other payables*	–	(122,688)	(122,688)				
	<u>–</u>	<u>(179,148)</u>	<u>(179,148)</u>				

Excludes prepayments

* Excludes deferred income and other long term employee benefits

6 Profit before tax

Profit before tax has been arrived after charging/(crediting):

	Group			
	6 months ended 31 December 2022 S\$'000	6 months ended 31 December 2021 S\$'000	12 months ended 31 December 2022 S\$'000	12 months ended 31 December 2021 S\$'000
Contributions to defined contribution plans	8,159	17,043	23,486	31,321
Changes in fair value in investment properties	600	(414)	600	(414)
Foreign exchange loss / (gain)	411	(338)	1,349	(542)
(Gain) / Loss on disposal of property, plant and equipment, net	(33)	68	(18)	59
Impairment loss on intangible assets and goodwill	7,338	3,780	7,338	3,780
Impairment loss on property, plant and equipment	9,958	–	9,958	–
Interest expense:				
- bank loans	2,287	2,470	4,703	4,924
- subsidiary's non-controlling interest	803	820	1,639	856
- lease liabilities	319	259	540	576
Interest income	(2,161)	(299)	(2,740)	(634)
Jobs Growth Incentive (JGI), Jobs Support Scheme (JSS) grant, wage credit, Early contribution incentive	(484)	(5,476)	(6,524)	(11,992)
Property, plant and equipment written-off	1,201	1,220	1,244	1,278
Recovery of bad debts	(249)	(114)	(864)	(732)
Value of employee services received for issue of share options and share awards, included in staff costs	1,647	1,357	3,160	2,469
Write-off for stock obsolescence	272	351	381	351
Write-off for non-trade receivables	–	680	–	680

7 Taxation

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed consolidated statement of profit or loss are:

	Group			
	6 months ended 31 December 2022 S\$'000	6 months ended 31 December 2021 S\$'000	12 months ended 31 December 2022 S\$'000	12 months ended 31 December 2021 S\$'000
Current income tax expense	27,176	14,271	49,419	28,538
Current withholding tax expense	718	729	1,451	1,375
Deferred income tax expense relating to origination and reversal of temporary differences	(2,474)	2,235	(2,065)	2,086
	<u>25,420</u>	<u>17,235</u>	<u>48,805</u>	<u>31,999</u>
Adjustment for prior years				
Current income tax expense – Adjustment for prior years	51	(338)	187	(351)
Deferred tax expense – Adjustment for prior years	(990)	220	(990)	220
	<u>(939)</u>	<u>(118)</u>	<u>(803)</u>	<u>(131)</u>
Tax expense	<u>24,481</u>	<u>17,117</u>	<u>48,002</u>	<u>31,868</u>

8 Dividends

	Group			
	6 months ended 31 December 2022 S\$'000	6 months ended 31 December 2021 S\$'000	12 months ended 31 December 2022 S\$'000	12 months ended 31 December 2021 S\$'000
Dividends paid:				
Final dividend in respect of the previous financial year of 2.80 (2021: 2.00) cents per share	–	–	52,015	37,349

9 Net assets value

	Group		Company	
	31 December 2022 S\$	31 December 2021 S\$	31 December 2022 S\$	31 December 2021 S\$
Net asset value per ordinary share [C]	54.73 cents	51.43 cents	53.63 cents	45.75 cents

[C] The calculation of net asset value per ordinary share was based on 1,854,547,625 shares as at 31 December 2022 (31 December 2021: 1,868,290,025).

10 Intangible assets and goodwill

Group	Goodwill	Customer relationship	Membership rights	Software under development	Software	Total
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Cost						
At 1 January 2021	25,321	4,458	164	1,221	12,694	43,858
Additions	–	–	–	–	2,973	2,973
Transfer	–	–	–	(1,057)	1,057	–
Effects of movement in exchange rate	1,118	214	–	–	133	1,465
At 31 December 2021	26,439	4,672	164	164	16,857	48,296
Additions	–	–	–	–	241	241
Write-off	–	–	–	–	(116)	(116)
Transfer	–	–	–	(164)	164	–
Effects of movement in exchange rate	(1,938)	(375)	–	–	(372)	(2,685)
At 31 December 2022	24,501	4,297	164	–	16,774	45,736
Accumulated amortisation and impairment losses						
At 1 January 2021	4,088	1,793	76	–	3,757	9,714
Amortisation	–	376	–	–	2,225	2,601
Impairment loss	3,780	–	–	–	–	3,780
Effects of movement in exchange rate	249	93	–	–	29	371
At 31 December 2021	8,117	2,262	76	–	6,011	16,466
Amortisation	–	365	–	–	2,338	2,703
Write-off	–	–	–	–	(107)	(107)
Impairment loss	5,868	1,410	60	–	–	7,338
Effects of movement in exchange rate	(634)	(194)	–	–	(110)	(938)
At 31 December 2022	13,351	3,843	136	–	8,132	25,462
Carrying amounts						
At 1 January 2021	21,233	2,665	88	1,221	8,937	34,144
At 31 December 2021	18,322	2,410	88	164	10,846	31,830
At 31 December 2022	11,150	454	28	–	8,642	20,274

For the purposes of impairment testing, goodwill has been allocated to the Group's CGUs (operating divisions) as follows:

Group	Group	
	2022 S\$'000	2021 S\$'000
China clinics	8,211	15,364
Cambodia clinic	2,939	2,958
	11,150	18,322

The recoverable amounts of CGUs were based on its value in use, determined by discounting the pre-tax future cash flows to be generated from the continuing use of the CGUs.

10 Intangible assets and goodwill (cont'd)

Key assumptions used in the estimation of value in use were as follows:

Group	2022 %	2021 %
Discount rate	15.2 – 15.6	12.1 – 18.1
Terminal growth rate	2.0 – 3.0	2.0 – 3.0
Revenue growth rate for next five years	3.0 – 20.7	3.0 – 25.9

The discount rate was a pre-tax measure based on the rate of 10-year government bonds issued by the government in the relevant market and in the same currency as the cash flows, adjusted for a risk premium to reflect both the increased risk of investing in equities generally and the systematic risk of the specific CGU.

Five years of cash flows were included in the discounted cash flow model. A long-term growth rate into perpetuity has been determined as the nominal GDP rates for the countries in which the CGUs operate.

Revenue growth was projected based on expectation of future outcomes taking into account the average growth levels experienced over the past five years and the estimated growth for the next five years.

11 Property, plant and equipment

During the year ended 31 December 2022, the Group acquired assets amounting to S\$22,685,000 (31 December 2021: S\$60,727,000), disposed of assets amounting to S\$690,000 (31 December 2021: S\$4,285,000) and recognised impairment loss on fixed asset amounting to S\$9,958,000 (31 December 2021: Nil).

During the six months ended 31 December 2022, the Group acquired assets amounting to S\$14,679,000 (6 months ended 31 December 2021: S\$27,764,000), disposed of assets amounting to S\$658,000 (6 months ended 31 December 2021: S\$4,281,000) and recognised impairment loss on fixed asset amounting to S\$9,958,000 (31 December 2021: Nil).

12 Investment properties

	Group	
	2022 S\$'000	2021 S\$'000
Balance as at 1 January	274,000	294,600
Reclassification to property, plant and equipment	–	(21,014)
Changes in fair value	(600)	414
Balance as at 31 December	<u>273,400</u>	<u>274,000</u>

12 Investment properties (cont'd)

The Group's policy is for investment property to be measured at fair value for which the Group completes property valuations at least annually by independent registered valuers at the end of the year. Investment properties that are measured at fair value are stated at fair value as at 31 December 2022 based on valuation performed by independent professional valuer, Colliers International Consultancy & Valuation (Singapore) Pte Ltd, having appropriate recognised professional qualifications and recent experience in the location and category of property being valued.

The fair value measurement for investment properties of \$273,400,000 (2021: \$274,000,000) has been categorised as a Level 3 fair value based on the inputs to the valuation technique used.

Valuation technique and significant unobservable inputs

The following table shows the Group's valuation technique used in measuring the fair value of investment properties, as well as the significant unobservable inputs used.

Valuation technique	Significant unobservable inputs	Inter-relationship between key unobservable inputs and fair value measurement
Capitalisation and discounted cash flow approach	<ul style="list-style-type: none"> Capitalisation rates 3.50% to 5.50% (2021: 3.50% to 5.50%) Discount rates 7.00% (2021: 7.00%) Terminal yield rates 4.25% (2021: 4.25%) 	The estimated fair value varies inversely against the capitalisation rates and discount rates.

13 Loans and borrowings

	Group		Company	
	31 December 2022	31 December 2021	31 December 2022	31 December 2021
	S\$'000	S\$'000	S\$'000	S\$'000
Amount repayable within one year or on demand				
Unsecured bank loans	9,667	96,297	9,667	18,546
Amount repayable after one year				
Unsecured bank loans	63,376	77,914	10,000	37,914
Total loans and borrowings	73,043	174,211	19,667	56,460

14 Share capital

Company	2022		2021	
	No. of shares '000	\$'000	No. of shares '000	\$'000
Fully paid ordinary shares, with no par value:				
At 1 January	1,870,726	426,346	1,864,726	420,966
Issue of shares under share option scheme	6,546	6,033	5,902	5,301
Issue of shares under performance share plan	-	-	98	79
At 31 December	<u>1,877,272</u>	<u>432,379</u>	<u>1,870,726</u>	<u>426,346</u>

The total number of issued shares excluding treasury shares as at 31 December 2022 was 1,854,547,625 (31 December 2021: 1,868,290,025)

(i) Exercise of share options and share awards

During the year ended 31 December 2022, the Company issued a total of 6,546,000 new ordinary shares, upon the exercise of options under the Raffles Medical Group Share Option Schemes.

Exercise price per share	S\$0.78	S\$0.81	S\$1.04	S\$1.07	S\$1.09	S\$1.31
Number of new shares issued / treasury shares utilised	3,085,000	428,000	190,000	966,000	1,862,000	15,000

During the year, the company utilised 574,700 treasury shares pursuant to the Raffles Medical Group Performance Share Plan.

On 1 September 2022, options to subscribe for 8,700,000 ordinary shares at an exercise price of S\$1.37 were granted to 128 eligible participants pursuant to the Raffles Medical Group (2020) Share Option Scheme.

On 1 September 2022, 1,050,000 share awards were granted to 292 eligible participants pursuant to Raffles Medical Group (2020) Performance Share Plan.

As at 31 December 2022, there were outstanding options for conversion into 76,455,000 (31 December 2021: 75,145,000) ordinary shares.

As at 31 December 2022, the number of shares comprised in contingent awards granted under the Raffles Medical Group (2020) Performance Share Plan which has not been released was 2,615,200 (31 December 2021: 2,564,000).

14 Share capital (cont'd)

(ii) Treasury shares

The Company holds 22,725,300 treasury shares as at 31 December 2022 (31 December 2021: 2,436,900).

The treasury shares held by the Company as at 31 December 2022 represent 1.23% (31 December 2021: 0.13%) of the total number of issued shares (excluding treasury shares).

	Number of treasury shares
Balance as at 1 January 2022	2,436,900
Acquisition of treasury shares	20,863,100
Use of treasury shares	(574,700)
Balance as at 31 December 2022	22,725,300

(iii) Subsidiary holdings

There is no subsidiary holdings as at 31 December 2022 (31 December 2021: Nil).

There were no sales, transfers, cancellation and/or use of subsidiary holdings as at 31 December 2022 (31 December 2021: Nil).

15 Subsequent events

There are no known subsequent events which led to adjustments to this set of financial statements.

Other Information Required by Listing Rule Appendix 7.2

1 Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.

The financial statements of Raffles Medical Group Ltd (the Company) and its subsidiaries (the Group), which comprise the consolidated statement of financial position of the Group and the statement of financial position of the Company as at 31 December 2022, the consolidated statement of profit or loss, consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows of the Group for the year then ended, and notes to the financial statements have been audited in accordance with Singapore Standards on Auditing. A copy of the Independent Auditors' report is attached.

The condensed consolidated statement of profit or loss and other comprehensive income and condensed consolidated statement of cash flows for the six-month period ended 31 December 2022 and certain explanatory notes have not been audited or reviewed.

2 A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:-

- (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and
- (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.

With the reopening of air-borders and the relaxation of COVID-19 related protocols in 2H 2022, the Group saw a return of foreign patients seeking medical treatment in Singapore. Concurrently, the Group's COVID-19 activities relating to vaccination centres also tapered off in 2H 2022 whilst some of its community treatment facilities (CTF) continued to evolve into step-down care facilities.

The Group's operations in China for most of FY 2022 continued to be impacted by the country's zero-tolerance COVID-19 policy. Although all its 3 China hospitals continued to operate during the respective lockdowns, **RafflesChinaHealthcare's** hospital operations faced staffing constraints as well as interruption to patients' access to our hospitals. When China relaxed its zero-tolerance policy for COVID-19 in December 2022, the Group's 3 hospitals supported the local community in government-led COVID-19 initiatives during this period.

In FY 2022, the Group posted revenue growth of **5.9%** to **S\$766.5** million from **S\$723.8** million in FY 2021. Reflecting the return of patients to our clinics, revenue from the Healthcare division grew by **8.6%** to **S\$498.3** million. The Group's Hospital Services division, reported lower revenue by **8.6%** to **S\$316.3** million, due to a decrease in the Polymerase Chain Reaction (PCR) diagnostic tests carried out in FY 2022 as compared to FY 2021.

Better cost control and deployment of manpower, together with lower inventories and consumables used, resulted in the Group's earnings before interest, taxes, depreciation and amortisation (EBITDA) growing **47.0%** to **S\$236.1** million in FY 2022, from **S\$160.6** million in FY 2021. Profit After Tax and Minority Interests (PATMI) grew **70.5%** to **S\$143.5** million in FY 2022, from **S\$84.2** million in FY 2021.

For the financial year ended 31 December 2022, the Group generated cash from operating activities amounting to **S\$196.2** million. As at 31 December 2022, the Group remained in a net cash position with **S\$252.1** million in cash and cash equivalents and **S\$96.1** million of debt, after net repayment of bank loans and lease liabilities of **S\$106.6** million, payment of dividends of **S\$52.0** million in cash and executing share buy-back amounting to **S\$24.3** million in value.

The Directors are pleased to recommend a final ordinary dividend of **3.8** cents per share for FY 2022 in view of the Group's strong performance, an increase of **35.7%** as compared to the previous year.

3 Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

The current financial year's results are in line with the Directors' expectations as disclosed in the Group's 1H 2022 results announcement and Q3 2022 media release.

4 A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

As the world adapts to living with COVID-19, global travel has resumed. Foreign and local patients are returning for treatment at **RafflesHospital**, **RafflesMedical** and **RafflesDental** branches. The Group's core healthcare business in Singapore is expected to continue its growth and expansion whereas the non core COVID-19 related business is expected to phase out. With the relaxation of COVID-19 containment policies in China, **RafflesChinaHealthcare** will benefit from the lifting of travel restrictions. Local and expatriate patients can now return to seek treatment at our China hospitals and medical clinics.

Across the Group, we offer a suite of healthcare solutions that can meet the varying needs of corporate and individual clients. To this end, we continue to evolve and work with key corporate customers and clients across the various geographies in which we operate, to develop and offer integrated healthcare services solutions tailored to meet their organisations' needs.

The global economy continues to face headwinds which can significantly slow down the economies of countries where the Group operates. Higher inflation and interest rates remain a threat and may dampen the demand for high-end healthcare services. Supply chain and labour constraints may also impact the Group negatively.

Against this challenging backdrop, opportunities abound. The Group will continue to explore new business opportunities as we continue improving the operational leverages of existing businesses.

Based on current conditions and barring unforeseen circumstances, the Directors expect the Group to remain profitable in FY 2023.

5 Dividend

(a) Current Financial Period Reported on

Any dividend declared for the current financial period reported on? Yes

Name of dividend	Proposed Final
Dividend Type	Ordinary
Dividend Amount per Share (in cents)	3.80 cents per ordinary share (one-tier tax)
Tax Rate	Tax Exempt

(b) Corresponding Period of the Immediately Preceding Financial Year

Any dividend declared for the corresponding period of the immediately preceding financial year? Yes

Name of dividend	Final
Dividend Type	Ordinary
Dividend Amount per Share (in cents)	1.80 cents per ordinary share (one-tier tax)
Tax Rate	Tax Exempt

Name of dividend	Final
Dividend Type	Special
Dividend Amount per Share (in cents)	1.00 cent per ordinary share (one-tier tax)
Tax Rate	Tax Exempt

(c) Date payable

The Directors are pleased to recommend a final dividend of 3.80 cents per share amounting approximately to S\$70.5 million in respect of the financial year ended 31 December 2022 for approval by the shareholders at the next Annual General Meeting to be convened on 28 April 2023.

The date of payment of the proposed dividends, if approved at the Annual General Meeting, will be announced at a later date.

(d) Books closure date

The books closure date will be announced at a later date.

(e) Scrip Dividend Scheme

The Scrip Dividend Scheme will not be applicable to the final dividend this year.

6 If no dividend has been declared/recommended, a statement to that effect.

Not applicable.

7 If the group has obtained a general mandate from shareholders for Interested Parties Transactions (IPTs), the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Company did not obtain a general mandate from shareholders for IPTs.

8 Confirmation pursuant to Rule 720 (1) of the Listing Manual

The Company confirms that it has procured undertakings from all its Directors and executive officers (in the format set out in Appendix 7.7) under Rule 720 (1) of the Listing Manual.

9 In the review of performance, the factors leading to any material changes in contributions to turnover and earnings by the business or geographical segments.

Please refer to Item 2.

10 A breakdown of sales.

		Group		
		2022 S\$'000	2021 S\$'000	Change %
(a)	Revenue reported for first half year	382,304	343,815	11.2
(b)	Operating profit after tax before deducting non-controlling interests reported for first half year	59,962	38,840	54.4
(c)	Revenue reported for second half year	384,233	379,976	1.1
(d)	Operating profit after tax before deducting non-controlling interests reported for second half year	83,740	44,876	86.6

- 11 Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(13). If there are no such persons, the issuer must make an appropriate negative statement.

Name	Age	Family relationship with any director and/or substantial shareholder	Current position and duties, and the year the position was held	Details of changes in duties and position held, if any, during the year
Dr Loo Choon Yong	74	Father of Dr Sarah Lu Qinghui	Executive Chairman of Raffles Medical Group (RMG) Ltd since 1997, having overall executive responsibility for the business direction, strategies and management of the RMG group of companies.	Nil
Dr Sarah Lu Qinghui	41	Daughter of Dr Loo Choon Yong	(1) Executive and Non-Independent Director, 1 June 2020 (2) Consultant Breast Surgeon, Raffles Hospital Pte Ltd, 1 June 2020	Nil

BY ORDER OF THE BOARD

Kimmy Goh
Company Secretary

27 February 2023